Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Other Non Operating Income (2017 - 2025)

Historic Other Non Operating Income for Akebia Therapeutics (AKBA) over the last 9 years, with Q3 2025 value amounting to -$10000.0.

  • Akebia Therapeutics' Other Non Operating Income rose 4117.65% to -$10000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $175000.0, marking a year-over-year increase of 10588.24%. This contributed to the annual value of -$517000.0 for FY2024, which is 15828.64% down from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' Other Non Operating Income is -$10000.0, which was up 4117.65% from -$28000.0 recorded in Q2 2025.
  • Akebia Therapeutics' 5-year Other Non Operating Income high stood at $1.3 million for Q2 2021, and its period low was -$517000.0 during Q1 2024.
  • For the 5-year period, Akebia Therapeutics' Other Non Operating Income averaged around $336000.0, with its median value being $247500.0 (2023).
  • Per our database at Business Quant, Akebia Therapeutics' Other Non Operating Income surged by 60434.78% in 2022 and then plummeted by 29000.0% in 2024.
  • Quarter analysis of 5 years shows Akebia Therapeutics' Other Non Operating Income stood at $560000.0 in 2021, then fell by 22.5% to $434000.0 in 2022, then skyrocketed by 51.61% to $658000.0 in 2023, then crashed by 102.58% to -$17000.0 in 2024, then soared by 41.18% to -$10000.0 in 2025.
  • Its Other Non Operating Income stands at -$10000.0 for Q3 2025, versus -$28000.0 for Q2 2025 and $213000.0 for Q1 2025.